Antiviral Efficacy, Pharmacokinetics and Safety of BILN 2061 ZW in Patients With Chronic Hepatitis C Virus Infection
Phase 1
Completed
- Conditions
- Hepatitis C, Chronic
- Interventions
- Drug: BILN 2061 W, medium doseDrug: BILN 2061 W, high doseDrug: PlaceboDrug: BILN 2061 W, low dose
- First Posted Date
- 2014-08-27
- Last Posted Date
- 2014-08-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 51
- Registration Number
- NCT02226952
Tolerability and Pharmacokinetics of BIIB 722 CL Drinking Solution and of BIIB 722 CL Filmcoated Tablet in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: BIIB 722 CL solutionDrug: Placebo tabletDrug: Placebo solutionDrug: BIIB 722 CL tablet
- First Posted Date
- 2014-08-27
- Last Posted Date
- 2014-08-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 71
- Registration Number
- NCT02227030
Effect of Food on the Pharmacokinetics of BI 1060469 (Formulation Tablet) in Healthy Male Subjects
- First Posted Date
- 2014-08-26
- Last Posted Date
- 2015-05-12
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 16
- Registration Number
- NCT02225626
- Locations
- 🇩🇪
1333.44.1 Boehringer Ingelheim Investigational Site, Ingelheim, Germany
Safety, Tolerability and Pharmacokinetics of Single Rising Doses of BIIB 722 CL and HPβCD in Young Healthy Male Volunteers
- First Posted Date
- 2014-08-25
- Last Posted Date
- 2014-08-25
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 100
- Registration Number
- NCT02224079
Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of BI 653048 BS H3PO4 Capsule Assessing Endotoxin-induced Inflammatory Response in Healthy Male Subjects
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: PlaceboDrug: BI 653048 BSDrug: endotoxin escherichia coli (E. coli) lipopolysaccharide (LPS)
- First Posted Date
- 2014-08-25
- Last Posted Date
- 2014-08-25
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 56
- Registration Number
- NCT02224105
Single Dose Followed by Maintenance Dose Tolerance Study of BIIR 561 CL in Healthy Elderly Male and Female Volunteers
- First Posted Date
- 2014-08-22
- Last Posted Date
- 2014-08-22
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 13
- Registration Number
- NCT02223507
Relative Bioavailability of a Linagliptin+Metformin Fixed Dose Combination Tablet Administered With and Without Food to Healthy Male and Female Subjects
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: Linagliptin/metformin FDCOther: high-fat, high caloric meal
- First Posted Date
- 2014-08-22
- Last Posted Date
- 2014-08-22
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 32
- Registration Number
- NCT02223026
Single Increasing Dose Tolerance Study in Healthy Male Volunteers of BIIR 561 CL
- First Posted Date
- 2014-08-22
- Last Posted Date
- 2014-08-22
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 84
- Registration Number
- NCT02222974
Relative Bioavailability and Tolerability of Various Experimental Formulations of BIBV 308 SE in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: BIBV 308 SE solutionDrug: BIBV 308 SE capsule 1Drug: BIBV 308 SE capsule 2
- First Posted Date
- 2014-08-22
- Last Posted Date
- 2014-08-22
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 9
- Registration Number
- NCT02223000
Relative Bioavailability and Tolerability of Two New Different Extended Release Capsules of BIBV 308 SE, Versus a Solution of BIBV 308 SE in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: BIBV 308 SE solutionDrug: BIBV 308 SE capsule LDrug: BIBV 308 SE capsule S
- First Posted Date
- 2014-08-22
- Last Posted Date
- 2014-08-22
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 9
- Registration Number
- NCT02223013